drugset / Trial / NCT03952923
CD19-CAR-T in B-cell Malignancies Patients
Phase 1
Completed
11 enrolled
Hebei Yanda Ludaopei Hospital
Avalon GloboCare Corp. · collabChina Immunotech (Beijing) Biotechnology Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, single arm, open-lable phase I study to determine the safety and efficacy of CD19-CAR-T cells in patients with refractory and relapsed B-cell malignancies.
Timeline
- Start
- 2019-08-01
- Primary completion
- 2021-01-01
- Completion
- 2021-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19 CAR-T cells | Cell therapy | — | Other |
| Background | Cyclophosphamide | Other / unclassified | 250 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |